Access the full text.
Sign up today, get DeepDyve free for 14 days.
Ge Zhang, Wan-li Liu, Lin Zhang, Jun-ye Wang, M. Kuang, Peng Liu, Yue-hao Lin, Shuqin Dai, Jun Du (2011)Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+ T-Cell Functions in Esophageal Squamous Cell Carcinoma
Clinical and Developmental Immunology, 2011
Rikke Holmgaard, D. Zamarin, Yanyun Li, Billel Gasmi, D. Munn, J. Allison, T. Merghoub, J. Wolchok (2015)Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Cell reports, 13 2
E. Sato, S. Olson, Jiyoung Ahn, B. Bundy, H. Nishikawa, F. Qian, A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, J. Kepner, Tosin Odunsi, G. Ritter, S. Lele, Yao-Tseng Chen, H. Ohtani, L. Old, K. Odunsi (2005)Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Proceedings of the National Academy of Sciences of the United States of America, 102 51
M. Rijnders, R. Wit, J. Boormans, M. Lolkema, A. Veldt (2017)Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
European urology, 72 3
N. Bahary, I. Garrido-Laguna, P. Cinar, M. O'Rourke, B. Somer, Asha Nyak-Kapoor, J. Lee, D. Munn, E. Kennedy, N. Vahanian, C. Link, A. Wang-Gillam (2016)Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.
Journal of Clinical Oncology, 34
Nobuhiko Nakamura, T. Hara, M. Shimizu, Ryoko Mabuchi, J. Nagano, T. Ohno, Takahiro Kochi, Masaya Kubota, Y. Shirakami, Naoe Goto, Hiroyasu Ito, Kuniaki Saito, Takuji Tanaka, H. Moriwaki, H. Tsurumi (2015)Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
International Journal of Hematology, 102
Soranobu Ninomiya, T. Hara, H. Tsurumi, Masato Hoshi, N. Kanemura, Naoe Goto, S. Kasahara, M. Shimizu, Hiroyasu Ito, Kuniaki Saito, Y. Hirose, Tetsuya Yamada, Takeshi Takahashi, M. Seishima, T. Takami, H. Moriwaki (2011)Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
Annals of Hematology, 90
O. Hamid, T. Bauer, A. Spira, A. Olszanski, S. Patel, J. Wasser, David Smith, A. Balmanoukian, C. Aggarwal, E. Schmidt, Yufan Zhao, H. Gowda, T. Gangadhar (2017)Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology, 35
J. Mezrich, J. Fechner, Xiaoji Zhang, Brian Johnson, W. Burlingham, C. Bradfield (2010)An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
The Journal of Immunology, 185
Fang Yuan, Yinghong Liu, Xiao Fu, Junxiang Chen (2012)Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 37 7
S. Corm, C. Berthon, M. Imbenotte, V. Biggio, M. Lhermitte, C. Dupont, I. Briche, B. Quesnel (2009)Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.
Leukemia research, 33 3
Madhav Sharma, R. Shinde, T. McGaha, Lei Huang, Rikke Holmgaard, J. Wolchok, M. Mautino, E. Celis, A. Sharpe, Loise Francisco, J. Powell, H. Yagita, A. Mellor, B. Blazar, D. Munn (2015)The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
Science Advances, 1
H. Koblish, M. Hansbury, Kevin Bowman, Gengjie Yang, C. Neilan, P. Haley, T. Burn, P. Waeltz, R. Sparks, E. Yue, A. Combs, P. Scherle, K. Vaddi, J. Fridman (2010)Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Molecular Cancer Therapeutics, 9
P. Nghiem, S. Bhatia, E. Lipson, R. Kudchadkar, Natalie Miller, L. Annamalai, S. Berry, E. Chartash, A. Daud, S. Fling, P. Friedlander, H. Kluger, H. Kohrt, Lisa Lundgren, K. Margolin, A. Mitchell, T. Olencki, D. Pardoll, S. Reddy, E. Shantha, W. Sharfman, E. Sharon, L. Shemanski, M. Shinohara, J. Sunshine, J. Taube, John Thompson, S. Townson, J. Yearley, S. Topalian, M. Cheever (2016)PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
The New England journal of medicine, 374 26
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
The New England journal of medicine, 364 26
V. Karanikas, M. Zamanakou, T. Kerenidi, J. Dahabreh, A. Hevas, M. Nakou, K. Gourgoulianis, A. Germenis (2007)Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer
Cancer Biology & Therapy, 6
A. Muller, J. DuHadaway, P. Donover, E. Sutanto‐Ward, G. Prendergast, G. Prendergast (2005)Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
Nature Medicine, 11
Mehler Ah, Knox We (1950)The conversion of tryptophan to kynurenine in liver. II. The enzymatic hydrolysis of formylkynurenine.
Journal of Biological Chemistry, 187
O. Hamid, T. Gajewski, A. Frankel, T. Bauer, A. Olszanski, J. Luke, A. Balmanoukian, E. Schmidt, B. Sharkey, J. Maleski, M. Jones, T. Gangadhar (2017)1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
Annals of Oncology, 28
Tomoko Inaba, K. Ino, H. Kajiyama, K. Shibata, E. Yamamoto, S. Kondo, T. Umezu, A. Nawa, O. Takikawa, F. Kikkawa (2010)Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
Gynecologic oncology, 117 3
K. Mitsuka, T. Kawataki, E. Satoh, T. Asahara, T. Horikoshi, H. Kinouchi (2013)Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas.
Neurosurgery, 72 6
F. Ichihara, K. Kono, Akihiro Takahashi, Hiromichi Kawaida, H. Sugai, H. Fujii (2003)Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9 12
H. Urakawa, Y. Nishida, H. Nakashima, Y. Shimoyama, S. Nakamura, N. Ishiguro (2009)Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Clinical & Experimental Metastasis, 26
M. Belladonna, C. Volpi, R. Bianchi, C. Vacca, C. Orabona, M. Pallotta, L. Boon, S. Gizzi, M. Fioretti, U. Grohmann, P. Puccetti (2008)Cutting Edge: Autocrine TGF-β Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells1
The Journal of Immunology, 181
L. Ivashkiv, L. Donlin (2013)Regulation of type I interferon responses
Nature Reviews Immunology, 14
U. Liyanage, T. Moore, H. Joo, Yoshiyuki Tanaka, V. Herrmann, G. Doherty, J. Drebin, S. Strasberg, T. Eberlein, P. Goedegebuure, D. Linehan (2002)Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1
The Journal of Immunology, 169
Ryoko Mabuchi, T. Hara, Takuro Matsumoto, Y. Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, J. Kitagawa, N. Kanemura, Naoe Goto, M. Shimizu, Hiroyasu Ito, Yasuko Yamamoto, Kuniaki Saito, H. Moriwaki, H. Tsurumi (2016)High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
Leukemia & Lymphoma, 57
Qingsheng Li, J. Harden, Charles Anderson, N. Egilmez (2016)Tolerogenic Phenotype of IFN-γ–Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop
The Journal of Immunology, 197
N. Bahary, I. Garrido-Laguna, A. Wang-Gillam, Asha Nyak-Kapoor, E. Kennedy, N. Vahanian, C. Link (2016)Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
Journal of Clinical Oncology, 34
P. Hwu, M. Du, R. Lapointe, M. Do, Milton Taylor, H. Young (2000)Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation
The Journal of Immunology, 164
T. Gangadhar, B. Schneider, T. Bauer, J. Wasser, A. Spira, S. Patel, A. Balmanoukian, J. Bauml, E. Schmidt, Yufan Zhao, Mark Jones, A. Tarhini (2017)Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology, 35
Robert Ferris, G. Blumenschein, J. Fayette, J. Guigay, A. Colevas, L. Licitra, K. Harrington, S. Kasper, E. Vokes, C. Even, F. Worden, Nabil Saba, L. Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. Geese, J. Kopit, James Shaw, Maura Gillison (2016)Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
The New England journal of medicine, 375 19
R. Speeckaert, K. Vermaelen, N. Geel, P. Autier, J. Lambert, M. Haspeslagh, M. Gele, K. Thielemans, B. Neyns, N. Roche, N. Verbeke, P. Deron, M. Speeckaert, L. Brochez (2012)Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
European journal of cancer, 48 13
K. Laimer, Birgit Troester, F. Kloss, G. Schafer, P. Obrist, A. Perathoner, J. Laimer, G. Brandacher, M. Rasse, R. Margreiter, A. Amberger (2011)Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.
Oral oncology, 47 5
K. Pan, Hui Wang, Minshan Chen, Hua-kun Zhang, D. Weng, Jun Zhou, Wei Huang, Jian‐jun Li, Hai-feng Song, J. Xia (2008)Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Journal of Cancer Research and Clinical Oncology, 134
D. Munn, Madhav Sharma, B. Baban, H. Harding, Yuhong Zhang, D. Ron, A. Mellor (2005)GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
Immunity, 22 5
E. Vasil'eva, V. Nikolin, N. Popova, E. Lushnikova, V. Kaledin (2010)Inhibitor of Indoleamine-2,3-Dioxygenase 1-Methyl-D-Tryptophan Can Stimulate the Growth of Immunogenic Tumors
Bulletin of Experimental Biology and Medicine, 149
H. Soliman, S. Minton, H. Han, R. Ismail-Khan, Anthony Neuger, F. Khambati, D. Noyes, R. Lush, A. Chiappori, John Roberts, C. Link, N. Vahanian, M. Mautino, H. Streicher, D. Sullivan, S. Antonia (2016)A phase I study of indoximod in patients with advanced malignancies
L. Platanias (2005)Mechanisms of type-I- and type-II-interferon-mediated signalling
Nature Reviews Immunology, 5
G. Brandacher, A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, C. Winkler, E. Werner, G. Werner-Felmayer, H. Weiss, Georg G√∂bel, R. Margreiter, Alfred K√∂nigsrainer, D. Fuchs, A. Amberger (2006)Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research, 12
R. Perez, Matthew Riese, K. Lewis, M. Saleh, A. Daud, J. Berlin, James Lee, S. Mukhopadhyay, Li Zhou, G. Serbest, O. Hamid (2017)Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
Journal of Clinical Oncology, 35
D. Ferns, I. Kema, M. Buist, H. Nijman, G. Kenter, E. Jordanova (2015)Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
Shintaro Iwama, A. Remigis, M. Callahan, S. Slovin, J. Wolchok, P. Caturegli (2014)Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Science Translational Medicine, 6
Tomoko Hayashi, J. Mo, Xing-mu Gong, C. Rossetto, A. Jang, L. Beck, Gregory Elliott, I. Kufareva, R. Abagyan, D. Broide, Jongdae Lee, E. Raz (2007)3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis
Proceedings of the National Academy of Sciences, 104
Anna Manlapat, David Kahler, P. Chandler, D. Munn, A. Mellor (2007)Cell‐autonomous control of interferon type I expression by indoleamine 2,3‐dioxygenase in regulatory CD19+ dendritic cells
European Journal of Immunology, 37
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, C. Cowey, C. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. Ferrucci, A. Hill, J. Wagstaff, M. Carlino, J. Haanen, M. Maio, I. Márquez-Rodas, G. McArthur, P. Ascierto, G. Long, M. Callahan, M. Postow, M. Postow, K. Grossmann, M. Sznol, B. Dréno, L. Bastholt, A. Yang, L. Rollin, C. Horak, F. Hodi, J. Wolchok, J. Wolchok (2015)Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
The New England journal of medicine, 373 1
J. Jacquemier, F. Bertucci, P. Finetti, B. Esterni, E. Charafe-Jauffret, Marie‐Laure Thibult, G. Houvenaeghel, B. Eynde, D. Birnbaum, D. Olive, L. Xerri (2012)High expression of indoleamine 2,3‐dioxygenase in the tumour is associated with medullary features and favourable outcome in basal‐like breast carcinoma
International Journal of Cancer, 130
J. Sznurkowski, A. Żawrocki, J. Emerich, Katarzyna Sznurkowska, W. Biernat (2011)Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests.
Gynecologic oncology, 122 2
Haidong Dong, G. Zhu, K. Tamada, Lieping Chen (1999)B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine, 5
O. Hamid, T. Bauer, A. Spira, David Smith, A. Olszanski, A. Tarhini, P. Lara, T. Gajewski, J. Wasser, S. Patel, V. Borges, A. Balmanoukian, E. Schmidt, Yufan Zhao, Mark Jones, T. Gangadhar (2017)Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology, 35
S. Spranger, R. Spaapen, Y. Zha, Jason Williams, Yuru Meng, T. Ha, T. Gajewski (2013)Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Science Translational Medicine, 5
F. Fallarino, U. Grohmann, C. Vacca, C. Orabona, A. Spreca, M. Fioretti, P. Puccetti (2003)T cell apoptosis by kynurenines.
Advances in experimental medicine and biology, 527
Tomoko Inaba, K. Ino, H. Kajiyama, E. Yamamoto, K. Shibata, A. Nawa, T. Nagasaka, H. Akimoto, O. Takikawa, F. Kikkawa (2009)Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Gynecologic oncology, 115 2
Lars Ormandy, Tina Hillemann, H. Wedemeyer, M. Manns, T. Greten, F. Korangy (2005)Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Cancer research, 65 6
D. Wainwright, I. Balyasnikova, Alan Chang, Atique Ahmed, Kyung-Sub Moon, B. Auffinger, Alex Tobias, Yu Han, M. Lesniak (2012)IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Clinical Cancer Research, 18
Miho Takao, A. Okamoto, T. Nikaido, M. Urashima, S. Takakura, M. Saito, M. Saito, S. Okamoto, O. Takikawa, H. Sasaki, M. Yasuda, K. Ochiai, Tadao Tanaka (2007)Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Oncology reports, 17 6
Haiyun Liu, Lei Huang, J. Bradley, Kebin Liu, Kankana Bardhan, D. Ron, A. Mellor, D. Munn, T. McGaha (2013)GCN2-Dependent Metabolic Stress Is Essential for Endotoxemic Cytokine Induction and Pathology
Molecular and Cellular Biology, 34
D. Munn, Min Zhou, J. Attwood, I. Bondarev, S. Conway, B. Marshall, Corrie Brown, A. Mellor (1998)Prevention of allogeneic fetal rejection by tryptophan catabolism.
Science, 281 5380
J. Brody, C. Costantino, A. Berger, Takami Sato, M. Lisanti, C. Yeo, R. Emmons, A. Witkiewicz (2009)Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
Cell Cycle, 8
H. Lemos, Eslam Mohamed, Lei Huang, R. Ou, Gabriela Pacholczyk, A. Arbab, D. Munn, A. Mellor (2016)STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Cancer research, 76 8
S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou, F. Carbonnel, C. Cauquil, P. Chanson, P. Chanson, M. Collins, A. Durrbach, S. Ederhy, S. Feuillet, H. François, J. Lazarovici, J. Pavec, J. Pavec, E. Martin, C. Mateus, Jean-Marie Michot, D. Samuel, Jeanine Soria, C. Robert, A. Eggermont, A. Marabelle (2016)Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 4
H. Burris, M. Gordon, M. Hellmann, P. LoRusso, L. Emens, F. Hodi, C. Lieu, J. Infante, F. Tsai, J. Eder, J. Cleary, D. Jelovac, A. Tsuhako, L. Mueller, R. Lin, K. Morrissey, S. Mahrus, R. Morley, A. Pirzkall, S. Davis (2017)A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.
Journal of Clinical Oncology, 35
J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, M. Kanai, Y. Mori, S. Matsumoto, S. Chikuma, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, Akihiko Ueda, Y. Hosoe, S. Morita, M. Yokode, Akira Shimizu, T. Honjo, I. Konishi (2015)Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34
T. Yoshikawa, T. Hara, H. Tsurumi, Naoe Goto, Masato Hoshi, J. Kitagawa, N. Kanemura, S. Kasahara, Hiroyasu Ito, M. Takemura, Kuniaki Saito, M. Seishima, T. Takami, H. Moriwaki (2010)Serum concentration of L‐kynurenine predicts the clinical outcome of patients with diffuse large B‐cell lymphoma treated with R‐CHOP
European Journal of Haematology, 84
F. Fallarino, U. Grohmann, S. You, Barbara Mcgrath, D. Cavener, C. Vacca, C. Orabona, R. Bianchi, M. Belladonna, C. Volpi, P. Santamaria, M. Fioretti, P. Puccetti (2006)The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1
The Journal of Immunology, 176
M. Denison, A. Pandini, Scott Nagy, E. Baldwin, L. Bonati (2002)Ligand binding and activation of the Ah receptor.
Chemico-biological interactions, 141 1-2
T. Gangadhar, O. Hamid, David Smith, T. Bauer, J. Wasser, J. Luke, A. Balmanoukian, D. Kaufman, Yufan Zhao, J. Maleski, L. Leopold, T. Gajewski (2015)Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
Journal for Immunotherapy of Cancer, 3
Liufu Deng, H. Liang, M. Xu, Xuanming Yang, Byron Burnette, A. Arina, Xiao-Dong Li, H. Mauceri, M. Beckett, T. Darga, Xiaona Huang, T. Gajewski, Zhijian Chen, yang-xin fu, R. Weichselbaum (2014)STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Immunity, 41 5
Qi Chen, Lijun Sun, Zhijian Chen (2016)Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Nature Immunology, 17
A. Ribas, O. Hamid, A. Daud, F. Hodi, J. Wolchok, R. Kefford, R. Kefford, A. Joshua, A. Patnaik, W. Hwu, J. Weber, T. Gangadhar, P. Hersey, R. Dronca, R. Joseph, H. Zarour, B. Chmielowski, D. Lawrence, A. Algazi, N. Rizvi, Brianna Hoffner, C. Mateus, K. Gergich, Jill Lindia, M. Giannotti, Xiaoyun Li, S. Ebbinghaus, S. Kang, C. Robert (2016)Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA, 315 15
K. Fukuno, T. Hara, H. Tsurumi, Y. Shibata, Ryoko Mabuchi, Nobuhiko Nakamura, J. Kitagawa, M. Shimizu, Hiroyasu Ito, Kuniaki Saito, H. Moriwaki (2015)Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics
Leukemia & Lymphoma, 56
K. Ino, N. Yoshida, H. Kajiyama, K. Shibata, E. Yamamoto, K. Kidokoro, N. Takahashi, M. Terauchi, A. Nawa, S. Nomura, T. Nagasaka, O. Takikawa, F. Kikkawa (2006)Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
British Journal of Cancer, 95
O. Hayaishi, R. Yoshida (2008)Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide.
Ciba Foundation symposium, 65
T Sasada, M Kimura, Y Yoshida (2003)CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression
A. Spira, O. Hamid, T. Bauer, V. Borges, J. Wasser, David Smith, A. Clark, E. Schmidt, Yufan Zhao, J. Maleski, T. Gangadhar (2017)Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.
Journal of Clinical Oncology, 35
Y. Urade, R. Yoshida, H. Kitamura, O. Hayaishi (1983)Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide.
The Journal of biological chemistry, 258 10
J. Taube, A. Klein, J. Brahmer, Haiying Xu, Xiaoyu Pan, J. Kim, Lieping Chen, D. Pardoll, S. Topalian, R. Anders (2014)Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Clinical Cancer Research, 20
S. Spranger, H. Koblish, B. Horton, P. Scherle, R. Newton, T. Gajewski (2014)Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
Journal for Immunotherapy of Cancer, 2
A. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, B. Grubeck‐Loebenstein (2003)Increase of regulatory T cells in the peripheral blood of cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9 2
C. Opitz, Ulrike Litzenburger, U. Opitz, F. Sahm, K. Ochs, C. Lutz, W. Wick, M. Plattén (2011)The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
PLoS ONE, 6
S. Tseng, M. Otsuji, K. Gorski, Xin Huang, J. Slansky, S. Pai, A. Shalabi, T. Shin, D. Pardoll, H. Tsuchiya (2001)B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
The Journal of Experimental Medicine, 193
P. Rodriguez, D. Quiceno, A. Ochoa (2007)L-arginine availability regulates T-lymphocyte cell-cycle progression.
Blood, 109 4
P. Ellis, E. Vella, Y. Ung (2017)Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Clinical lung cancer, 18 5
Carole Guillonneau, M. Hill, F. Hubert, Elise Chiffoleau, C. Hervé, Xian-liang Li, M. Heslan, C. Usal, L. Tesson, S. Ménoret, A. Saoudi, B. Mauff, R. Josien, M. Cuturi, I. Anegon (2007)CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFN-γ, and indoleamine 2,3-dioxygenase
Journal of Clinical Investigation, 117
L. Siu, K. Gelmon, Q. Chu, R. Pachynski, O. Alese, P. Basciano, Walker Kamilah, Priyam Mitra, Li Zhu, P. Phillips, J. Hunt, J. Desai (2017)Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Cancer Research, 77
Y. Şenbabaoğlu, Ron Gejman, A. Winer, Ming Liu, E. Allen, G. Velasco, Diana Miao, I. Ostrovnaya, E. Drill, Augustin Luna, Nils Weinhold, William Lee, B. Manley, D. Khalil, S. Kaffenberger, Ying-bei Chen, Ludmila Danilova, M. Voss, J. Coleman, P. Russo, V. Reuter, T. Chan, E. Cheng, D. Scheinberg, Ming Li, T. Choueiri, J. Hsieh, C. Sander, A. Hakimi (2016)Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
Genome Biology, 18
Yunlong Jia, Hongyan Wang, Yu Wang, Ting-ting Wang, Miao Wang, M. Ma, Y. Duan, Xianli Meng, Lihua Liu (2015)Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
International Journal of Cancer, 137
Xiangdong Liu, N. Shin, H. Koblish, Gengjie Yang, Qian Wang, K. Wang, L. Leffet, M. Hansbury, B. Thomas, M. Rupar, P. Waeltz, Kevin Bowman, Padmaja Polam, R. Sparks, E. Yue, Yanlong Li, R. Wynn, J. Fridman, T. Burn, A. Combs, R. Newton, P. Scherle (2010)Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Blood, 115 17
G. Freeman, A. Long, Yoshiko Iwai, K. Bourque, T. Chernova, H. Nishimura, L. Fitz, Nelly Malenkovich, Taku Okazaki, M. Byrne, H. Horton, L. Fouser, L. Carter, V. Ling, M. Bowman, B. Carreno, M. Collins, C. Wood, T. Honjo (2000)Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
The Journal of Experimental Medicine, 192
D. Munn, Madhav Sharma, Deyan Hou, B. Baban, J. Lee, S. Antonia, J. Messina, P. Chandler, P. Koni, A. Mellor (2004)Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
The Journal of clinical investigation, 114 2
D. Hoff, T. Ervin, F. Arena, E. Chiorean, J. Infante, M. Moore, T. Seay, S. Tjulandin, W. Ma, M. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Cutsem, Xinyu Wei, J. Iglesias, M. Renschler (2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
The New England journal of medicine, 369 18
Bin Shang, Yao Liu, Shu-juan Jiang, Yi Liu (2015)Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Scientific Reports, 5
C. Vogel, Dalei Wu, S. Goth, Jaeeun Baek, Anna Lollies, Rowena Domhardt, Annemarie Grindel, I. Pessah (2013)Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation
Immunology and Cell Biology, 91
I. Chevolet, R. Speeckaert, Marc Haspeslagh, Bart Neyns, V. Kruse, M. Schreuer, M. Gele, N. Geel, L. Brochez (2014)Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?
British Journal of Dermatology, 171
R. Riesenberg, C. Weiler, O. Spring, M. Eder, A. Buchner, T. Popp, M. Castro, R. Kammerer, O. Takikawa, R. Hatz, C. Stief, A. Hofstetter, W. Zimmermann (2007)Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma
Clinical Cancer Research, 13
K. Dubin, M. Callahan, Boyu Ren, R. Khanin, A. Viale, Lilan Ling, Daniel No, Asia Gobourne, E. Littmann, C. Huttenhower, E. Pamer, J. Wolchok (2016)Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Nature Communications, 7
C. Denkert, G. Minckwitz, J. Brase, B. Sinn, S. Gade, R. Kronenwett, B. Pfitzner, C. Salat, S. Loi, W. Schmitt, C. Schem, K. Fisch, S. Darb-Esfahani, K. Mehta, C. Sotiriou, S. Wienert, P. Klare, F. André, F. Klauschen, J. Blohmer, K. Krappmann, Marcus Schmidt, H. Tesch, S. Kümmel, P. Sinn, C. Jackisch, M. Dietel, T. Reimer, M. Untch, S. Loibl (2015)Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 9
Marisa Ryan, Jennifer Crow, R. Kahmke, S. Fisher, Z. Su, Walter Lee (2014)FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.
American journal of otolaryngology, 35 6
D. Levy, Chien-Kuo Lee (2002)What does Stat3 do?
The Journal of clinical investigation, 109 9
M. Pallotta, C. Orabona, C. Volpi, C. Vacca, M. Belladonna, R. Bianchi, G. Servillo, Cinzia Brunacci, M. Calvitti, S. Bicciato, E. Mazza, L. Boon, F. Grassi, M. Fioretti, F. Fallarino, P. Puccetti, U. Grohmann (2011)Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Nature Immunology, 12
Jin Ye, Hui Liu, Yanming Hu, Peng Li, Gehua Zhang, Yuan Li (2012)Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma
Virchows Archiv, 462
S. Moretti, Elisa Menicali, Pasquale Voce, Silvia Morelli, Sara Cantarelli, M. Sponziello, R. Colella, F. Fallarino, C. Orabona, A. Alunno, D. Biase, V. Bini, M. Mameli, S. Filetti, R. Gerli, A. Macchiarulo, R. Melillo, G. Tallini, M. Santoro, P. Puccetti, N. Avenia, E. Puxeddu (2014)Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
The Journal of clinical endocrinology and metabolism, 99 5
M. Mautino, Firoz Jaipuri, J. Waldo, Sanjeev Kumar, James Adams, C. Allen, Agnieszka Marcinowicz-Flick, D. Munn, N. Vahanian, C. Link (2013)Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
Cancer Research, 73
V. Folgiero, B. Goffredo, P. Filippini, R. Masetti, G. Bonanno, R. Caruso, V. Bertaina, A. Mastronuzzi, S. Gaspari, M. Zecca, G. Torelli, A. Testi, A. Pession, F. Locatelli, S. Rutella (2013)Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
W. Knox, A. Mehler (1950)The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine.
The Journal of biological chemistry, 187 1
Robert Chen, P. Zinzani, M. Fanale, P. Armand, N. Johnson, P. Brice, J. Radford, V. Ribrag, D. Molin, T. Vassilakopoulos, A. Tomita, B. Tresckow, M. Shipp, Yinghua Zhang, A. Ricart, A. Balakumaran, C. Moskowitz (2017)Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 19
S. Nam, Sehui Kim, J. Paik, T. Kim, D. Heo, C. Kim, Y. Jeon (2016)An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
Leukemia & Lymphoma, 57
A. Tanaka, S. Sakaguchi (2016)Regulatory T cells in cancer immunotherapy
Cell Research, 27
C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. Hassel, P. Rutkowski, C. McNeil, E. Kalinka‐Warzocha, K. Savage, M. Hernberg, C. Lebbé, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I. Waxman, V. Atkinson, P. Ascierto (2015)Nivolumab in previously untreated melanoma without BRAF mutation.
The New England journal of medicine, 372 4
Lei Huang, Lingqian Li, H. Lemos, P. Chandler, Gabriela Pacholczyk, B. Baban, G. Barber, Y. Hayakawa, T. McGaha, B. Ravishankar, D. Munn, A. Mellor (2013)Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
The Journal of Immunology, 191
Madhav Sharma, B. Baban, P. Chandler, Deyan Hou, Nagendra Singh, H. Yagita, M. Azuma, B. Blazar, A. Mellor, D. Munn (2007)Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
The Journal of clinical investigation, 117 9
G. Weinlich, C. Murr, Laura Richardsen, C. Winkler, D. Fuchs (2006)Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
T. Sasada, Motohide Kimura, Yuka Yoshida, M. Kanai, A. Takabayashi (2003)CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies
D. Le, J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, A. Skora, Brandon Luber, N. Azad, D. Laheru, B. Biedrzycki, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, Steven Duffy, R. Goldberg, A. Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. Hruban, L. Wood, N. Cuka, D. Pardoll, N. Papadopoulos, K. Kinzler, Shibin Zhou, Toby Cornish, J. Taube, R. Anders, J. Eshleman, B. Vogelstein, L. Diaz (2015)PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
The New England journal of medicine, 372 26
H. Lemos, Lei Huang, P. Chandler, Eslam Mohamed, G. Souza, Lingqian Li, Gabriela Pacholczyk, G. Barber, Y. Hayakawa, D. Munn, A. Mellor (2014)Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis
The Journal of Immunology, 192
M. Pelak, M. Śnietura, D. Lange, B. Nikiel, K. Pecka (2015)The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma.
Polish journal of pathology : official journal of the Polish Society of Pathologists, 66 4
S. Astigiano, B. Morandi, R. Costa, L. Mastracci, A. D'agostino, G. Ratto, G. Melioli, G. Frumento (2005)Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.
Neoplasia, 7 4
N. Hiraoka, K. Onozato, T. Kosuge, S. Hirohashi (2006)Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions
Clinical Cancer Research, 12
S. Löb, A. Königsrainer, D. Zieker, B. Brücher, H. Rammensee, G. Opelz, P. Terness (2008)IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Cancer Immunology, Immunotherapy, 58
Carsten Schaefer, GG Kim, A. Albers, K. Hoermann, EN Myers, T. Whiteside (2005)Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
British Journal of Cancer, 92
Merja Jaronen, F. Quintana (2014)Immunological Relevance of the Coevolution of IDO1 and AHR
Frontiers in Immunology, 5
O. Demaria, A. Gassart, Sanja Coso, N. Gestermann, J. Domizio, L. Flatz, O. Gaide, O. Michielin, P. Hwu, T. Petrova, F. Martinon, R. Modlin, D. Speiser, M. Gilliet (2015)STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Proceedings of the National Academy of Sciences, 112
R. Das, R. Verma, M. Sznol, C. Boddupalli, S. Gettinger, H. Kluger, M. Callahan, J. Wolchok, R. Halaban, M. Dhodapkar, K. Dhodapkar (2015)Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
The Journal of Immunology, 194
G. Feng, W. Dai, S. Gupta, G. Werner-Felmayer, H. Wachter, O. Takikawa, M. Taylor (1991)Analysis of interferon-gamma resistant mutants that are possibly defective in their signaling mechanism
Molecular and General Genetics MGG, 230
B. Baban, P. Chandler, Madhav Sharma, Jeanene Pihkala, P. Koni, D. Munn, A. Mellor (2009)IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1
The Journal of Immunology, 183
Lijie Zhai, Kristen Lauing, Alan Chang, M. Dey, J. Qian, Y. Cheng, M. Lesniak, D. Wainwright (2015)The role of IDO in brain tumor immunotherapy
Journal of Neuro-Oncology, 123
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine, 363 8
H. Zarour (2016)Reversing T-cell Dysfunction and Exhaustion in Cancer
Clinical Cancer Research, 22
Rikke Holmgaard, D. Zamarin, D. Munn, J. Wolchok, J. Allison (2013)Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
The Journal of Experimental Medicine, 210
R. Nanda, L. Chow, C. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, K. Pathiraja, G. Aktan, Jonathan Cheng, V. Karantza, L. Buisseret (2016)Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 21
A. Mellor, D. Munn (2004)Ido expression by dendritic cells: tolerance and tryptophan catabolism
Nature Reviews Immunology, 4
K. Ino, E. Yamamoto, K. Shibata, H. Kajiyama, N. Yoshida, M. Terauchi, A. Nawa, T. Nagasaka, O. Takikawa, F. Kikkawa (2008)Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
Clinical Cancer Research, 14
F. Quintana, G. Murugaiyan, M. Farez, M. Mitsdoerffer, A. Tukpah, Evan Burns, H. Weiner (2010)An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
Proceedings of the National Academy of Sciences, 107
T. Curiel, G. Coukos, L. Zou, Xavier Alvarez, P. Cheng, P. Mottram, Melina Evdemon-Hogan, J. Conejo-Garcia, Lin Zhang, M. Burow, Yun Zhu, Shuang Wei, Ilona Kryczek, B. Daniel, Alan Gordon, L. Myers, A. Lackner, M. Disis, K. Knutson, Lieping Chen, W. Zou (2004)Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Nature Medicine, 10
G. Beatty, P. O'dwyer, Jason Clark, Jack Shi, Kevin Bowman, P. Scherle, R. Newton, R. Schaub, J. Maleski, L. Leopold, T. Gajewski (2017)First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Clinical Cancer Research, 23
C. Robert, J. Schachter, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, Honghong Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas (2015)Pembrolizumab versus Ipilimumab in Advanced Melanoma.
The New England journal of medicine, 372 26
B. Ravishankar, Haiyun Liu, R. Shinde, K. Chaudhary, W. Xiao, J. Bradley, M. Koritzinsky, M. Madaio, T. McGaha (2015)The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity
Proceedings of the National Academy of Sciences, 112
Yan-fang Gao, R. Peng, Jiang Li, Ya Ding, Xing Zhang, Xiaojun Wu, Z. Pan, D. Wan, Y. Zeng, Xiao-shi Zhang (2009)The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
Journal of Translational Medicine, 7
C. Chambers, M. Krummel, B. Boitel, A. Hurwitz, Tim Sullivan, S. Fournier, D. Cassell, M. Brunner, J. Allison (1996)The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses
Immunological Reviews, 153
R. Jong, I. Kema, A. Boerma, H. Boezen, J. Want, Marloes Gooden, H. Hollema, H. Nijman (2012)Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
Gynecologic oncology, 126 3
Xiaoqian Liu, K. Lu, Li-li Feng, M. Ding, Jun-ming Gao, Xue-ling Ge, Xin Wang (2014)Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
Leukemia & Lymphoma, 55
A. Engin, I. Gonul, A. Engin, A. Karamercan, A. Dinçel, A. Dursun (2016)Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
World journal of gastroenterology, 22 13
Gaynor Bates, S. Fox, Cheng Han, R. Leek, J. García, A. Harris, A. Banham (2006)Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 34
D. Wainwright, Alan Chang, M. Dey, I. Balyasnikova, C. Kim, Alex Tobias, Y. Cheng, Julius Kim, J. Qiao, Lingjiao Zhang, Yu Han, M. Lesniak (2014)Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Clinical Cancer Research, 20
L. Ferdinande, C. Decaestecker, L. Verset, A. Mathieu, X. Lopez, A. Negulescu, T. Maerken, I. Salmon, C. Cuvelier, P. Demetter (2011)Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
British Journal of Cancer, 106
C. Jochems, M. Fantini, R. Fernando, Anna Kwilas, R. Donahue, Lauren Lepone, I. Grenga, Young-Seung Kim, M. Brechbiel, J. Gulley, R. Madan, C. Heery, J. Hodge, R. Newton, J. Schlom, K. Tsang (2016)The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
G. Gibney, O. Hamid, T. Gangadhar, J. Lutzky, A. Olszanski, T. Gajewski, B. Chmielowski, P. Boasberg, Yufan Zhao, Robert Newton, Peggy Scherle, Jill Bowman, J. Maleski, L. Leopold, Jeffrey Weber (2014)Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Journal of Clinical Oncology, 32
B. Creelan, S. Antonia, G. Bepler, T. Garrett, G. Simon, H. Soliman (2013)Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, Nicolas Parmentier, T. Boon, B. Eynde (2003)Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Nature Medicine, 9
Y. Latchman, C. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Yoshiko Iwai, A. Long, Julia Brown, Raquel Nunes, E. Greenfield, K. Bourque, V. Boussiotis, Laura Carter, B. Carreno, Nelly Malenkovich, H. Nishimura, Taku Okazaki, T. Honjo, A. Sharpe, G. Freeman (2001)PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology, 2
David Smith, T. Gajewski, O. Hamid, J. Wasser, A. Olszanski, S. Patel, R. Mamtani, E. Schmidt, Yufan Zhao, J. Maleski, T. Gangadhar (2017)Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology, 35
M. Chamuleau, A. Loosdrecht, C. Hess, J. Janssen, A. Zevenbergen, R. Delwel, P. Valk, B. Löwenberg, G. Ossenkoppele (2008)High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Haematologica, 93 12
Saikumar Karyala, Junhai Guo, M. Sartor, M. Medvedovic, A. Puga, P. Ryan, C. Tomlinson (2007)Different global gene expression profiles in benzo[a]pyrene-and dioxin-treated vascular smooth muscle cells of AHR-knockout and wild-type mice
Cardiovascular Toxicology, 4
H. Soliman, E. Jackson, Tony Neuger, C. Dees, Donald Harvey, H. Han, R. Ismail-Khan, S. Minton, N. Vahanian, C. Link, D. Sullivan, S. Antonia (2014)A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
E. Pfefferkorn (1984)Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan.
Proceedings of the National Academy of Sciences of the United States of America, 81 3
Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts both tolerogenic and pro-inflammatory effects and has a profound immunoregulatory role in the tumor microenvironment. Although the role of IDO in mediating peripheral acquired immunologic tolerance has been known for some time, its role in tumorigenesis and the subversion of anti-tumor immunity have only recently been appreciated. Small-molecule inhibitors of IDO1 and TDO are being evaluated as single agents and in combination with immune checkpoint blockade in a host of advanced cancers. In this review, we delineate the tolerogenic and pro-inflammatory effects of IDO as it relates to immune escape and discuss current clinical progress in this area.[Figure not available: see fulltext.]
Targeted Oncology – Springer Journals
Published: Jan 4, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.